| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 165,30 | 165,90 | 15:46 | |
| 164,90 | 165,70 | 15:42 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 167,45 | 1.266 | |||
| 166,95 | 300 | |||
| 166,60 | 1.200 | |||
| 166,55 | 249 | |||
| 166,50 | 50 | |||
| 166,40 | 300 | |||
| 166,00 | 54 | |||
| 165,95 | 160 | |||
| 165,90 | 214 | |||
| 165,85 | 214 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/idp.htm [/URL] | ||||
| 214 | 165,45 | |||
| 214 | 165,40 | |||
| 160 | 165,35 | |||
| 160 | 165,30 | |||
| 300 | 165,15 | |||
| 50 | 165,00 | |||
| 500 | 164,55 | |||
| 300 | 164,50 | |||
| 1.200 | 164,05 | |||
| 144 | 163,65 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 3.242 | 1,236 | 4.007 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 15:22:03 | 165,45 | 18 |
| Tagesumsatz Xetra | +2,30 +1,41 % | 58 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:24 | Alteogen Stock Up On Upto $579 Mln Deal With Biogen For Hybrozyme-Based Subcutaneous Biologics | 149 | AFX News | WESTON (dpa-AFX) - Shares of Alteogen Inc. (196170.KQ) gained around 6 percent on Thursday's trading in South Korea after the biopharma company announced that it has entered into an exclusive... ► Artikel lesen | |
| Mi | Biogen and Alteogen ink licensing deal for injectables | 3 | Seeking Alpha | ||
| BIOGEN Aktie jetzt für 0€ handeln | |||||
| Mi | Biogen pays $20M upfront to tap into Alteogen's subQ delivery tech | 4 | FiercePharma | ||
| Mi | Eisai and Biogen's new data shows Alzheimer's patients choose to stay on Leqembi long-term | 6 | PMLiVE | ||
| Fr | Biogen Inc.: Results from Real-World, Long-Term Treatment Persistence with LEQEMBI (lecanemab-irmb) in the United States Presented at AD/PD 2026 | 811 | GlobeNewswire (Europe) | TOKYO and CAMBRIDGE, Mass., March 20, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts... ► Artikel lesen |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 15:03 | EQS-News: Wall Street Wire: Verteidigungsboom trifft Biotech - MediWound könnte zu den unterschätzten Profiteuren zählen (NASDAQ: MDWD) | EQS Group (DE) | EQS-News: Wall Street Wire
/ Schlagwort(e): Sonstiges
Verteidigungsboom trifft Biotech - MediWound könnte zu den unterschätzten Profiteuren zählen (NASDAQ: MDWD)
26.03.2026... ► Artikel lesen | |
| 12:36 | Cognition Therapeutics, Inc.: Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update | GlobeNewswire (Europe) | -Advancing zervimesine clinical development in DLB psychosis - - Meeting with FDA Division of Psychiatry expected by mid-2026 -- Management conference call at 8:30 a.m. ET today - PURCHASE, N.Y.,... ► Artikel lesen | |
| 13:36 | Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results | GlobeNewswire (Europe) | - Closes Private Placement Financing of Up to $104.5 Million - Secures Orphan Drug Designations for QRX003 for Netherton Syndrome (NS) in the U.S. and Europe - Advances Proposed Expedited Regulatory... ► Artikel lesen | |
| 15:26 | Alligator Bioscience Publishes Annual Report for 2025 | ACCESS Newswire | LUND, SWEDEN / ACCESS Newswire / March 26, 2026 / Alligator Bioscience (Nasdaq Stockholm:ATORX) today announced that the Annual Report for 2025, as well as the company's Remuneration Report, has been... ► Artikel lesen | |
| 14:00 | Pulmatrix Inc.: Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan | PR Newswire | Combined company to operate as Eos SENOLYTIX, a first-in-class anti-aging biotechnology company
$19 million financings to advance lead clinical candidate PTC-2105 for sarcopenia and... ► Artikel lesen |